ADMA Biologics Investors Urged to Join Major Securities Fraud Class Action by Rosen Law Firm

Rosen Law Firm Calls ADMA Biologics Investors to Action

In a recent announcement, the Rosen Law Firm, a prominent name in investor rights litigation, has brought attention to the ongoing securities fraud lawsuit involving ADMA Biologics, Inc. (NASDAQ: ADMA). This legal action is particularly significant for those who purchased ADMA’s securities during the class period from August 9, 2024, to March 25, 2026. Investors are encouraged to be aware of the pivotal lead plaintiff deadline set for August 10, 2026.

What’s at Stake?

If you are among those who invested in ADMA Biologics during the mentioned time frame, you may have the opportunity to seek compensation without incurring any upfront fees. This is common practice in contingency fee arrangements, which ensure that clients do not bear the costs unless they win the case.

How to Participate

To join the class action lawsuit, investors can visit the dedicated page at Rosen Law Firm's website or reach out directly by calling Phillip Kim, Esq. at 866-767-3653, or via email at [email protected]. Furthermore, anyone interested in serving as a lead plaintiff—representing the interests of other investors—must file their motions by the deadline.

Background of the Case

The lawsuit has emerged as a response to allegations that ADMA Biologics misled investors through a series of materially false statements and failed disclosures. Key points in the allegations include:
1. Engagement in undisclosed transactions involving related parties.
2. Manipulative practices known as channel stuffing to overstate revenue.
3. Inadequate internal controls at the company.
4. Misrepresentation of ADMA Biologics’ operations and future prospects, which ultimately misled investors.

These revelations, when disclosed, reportedly caused significant financial harm to investors, leading to the filing of this lawsuit. The role of the Rosen Law Firm is to ensure that these investors have the representation they need to pursue their claims effectively.

Why Choose Rosen Law Firm?

The Rosen Law Firm is noted for its extensive experience in securities class actions and shareholder derivative litigation. The firm has a distinguished track record, including the largest settlement for a securities class action against a Chinese company. Their accolades further include being ranked as a leading firm in this field since 2013, showcasing a commitment to advocacy for investors on a global scale. In 2019 alone, the firm was able to recover over $438 million for investors, highlighting their effectiveness and dedication.

A Call for Awareness and Action

It’s important for all ADMA Biologics investors to remain informed and proactive in relation to this legal battle. Until a class is certified, individual participants should choose their counsel wisely or even consider remaining uninvolved until they can assess the situation further. However, being involved in this type of litigation not only affords an opportunity for financial recovery but also plays a vital role in holding companies accountable for their actions.

For ongoing updates or more information, stakeholders can follow the Rosen Law Firm on social media platforms like LinkedIn, Twitter, and Facebook. The firm is committed to ensuring that investors are kept in the loop regarding any developments in this case as well as other related matters.

In conclusion, with the lead plaintiff deadline approaching, it is crucial for potential claimants to act quickly and engage with experienced legal representation to navigate this complex situation. Investors should take this opportunity to advocate for their rights and seek redress through this class action lawsuit.